Early growth response protein 4 (EGR4) is a transcription factor, which belongs to immediate early genes family. It has four DNA binding domains and a zinc-finger motif. The EGR4 gene is mapped to human chromosome 2p13.2. It is expressed in the central nervous system and in murine testes.
Synonyms: Anti-NGFI-C; Anti-PAT133; Anti-early growth response 4
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Early growth response protein 4 (EGR4) binds to GC-rich Egr response element (ERE) and mediates inflammatory response. It is an important regulator for the development of hindbrain. Polymorphism in ERG4 gene impacts spermatogenesis and hence male fertility. Reduced expression of ERG4 is observed in male schizophrenia patients. EGR4 regulates gene expression and promotes proliferation in small cell lung cancer.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC